Rubric Capital Management (New York)’s Theravance Biopharma TBPH Stock Holding History

Rubric Capital Management (New York)’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-356,100	Closed	-$3.61M	–	102
2022 Q3	$3.61M	Buy	+356,100	New	+$3.34M	0.18%	70
2020 Q4	–	Sell	-550,747	Closed	-$8.14M	–	80
2020 Q3	$8.14M	Sell	550,747 -395,710	-42%	-$7.41M	0.76%	45
2020 Q2	$19.9M	Buy	946,457 +72,880	+8%	+$1.87M	2.29%	19
2020 Q1	$20.2M	Buy	873,577 +700,177	+404%	+$17.5M	3.19%	14
2019 Q4	$4.49M	Buy	+173,400	New	+$3.37M	0.51%	40

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Rubric Capital Management (New York)'s TBPH Position: Q4 2022 in Review

Rubric Capital Management (New York) sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 356,100 shares — an estimated $3.61M sold.

Rubric Capital Management (New York) first reported a position in TBPH in Q4 2019 and held it in 5 quarters. The position peaked at $20.2M in Q1 2020. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

Rubric Capital Management (New York) reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
Rubric Capital Management (New York) sold 356,100 Theravance Biopharma shares in Q4 2022, an estimated $3.61M.
Rubric Capital Management (New York) first reported a position in Theravance Biopharma in Q4 2019 and held it in 5 quarters.
Rubric Capital Management (New York)'s Theravance Biopharma position peaked at $20.2M in Q1 2020.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2022, filed 10 Feb 2023.